📣 VC round data is live. Check it out!

Jafron Biomedical Valuation Multiples

Discover revenue and EBITDA valuation multiples for Jafron Biomedical and similar public comparables like Nektar Therapeutics, Pfizer India, BioCryst Pharma, Jeol and more.

Jafron Biomedical Overview

About Jafron Biomedical

Jafron Biomedical Co Ltd is a China-based company engaged in the research, development, production, and sales of biomaterials and medical devices. It offers solutions for kidney disease, poisoning, rheumatic immune solution, critical illness and liver disease. The company's products include JFYC-100 pre-punching machine, DX-10 blood purifier, and HA resin hemoperfusion.


Founded

1989

HQ

China

Employees

N/A

Website

jafron.com

Financials (LTM)

Revenue: $305M
EBITDA: $147M

EV

$2B

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

Jafron Biomedical Financials

Jafron Biomedical reported last 12-month revenue of $305M and EBITDA of $147M.

In the same LTM period, Jafron Biomedical generated $241M in gross profit, $147M in EBITDA, and $86M in net income.

Revenue (LTM)


Jafron Biomedical P&L

In the most recent fiscal year, Jafron Biomedical reported revenue of $297M and EBITDA of $145M.

Jafron Biomedical is profitable as of last fiscal year, with gross margin of 79%, EBITDA margin of 49%, and net margin of 26%.

See analyst estimates for Jafron Biomedical
LTMLast FY202320242025202620272028
Revenue$305M$297M$284M$396M$297M
Gross Profit$241M$234M$227M$320M$234M
Gross Margin79%79%80%81%79%
EBITDA$147M$145M$99M$177M$124M
EBITDA Margin48%49%35%45%42%
EBIT Margin36%37%27%39%37%
Net Profit$86M$79M$65M$121M$79M
Net Margin28%26%23%31%26%

Financial data powered by Morningstar, Inc.

Jafron Biomedical Stock Performance

Jafron Biomedical has current market cap of $2B, and enterprise value of $2B.

Market Cap Evolution


Jafron Biomedical's stock price is $2.70.

Jafron Biomedical share price increased by 0.6% in the last 30 days, and decreased by 13.8% in the last year.

Jafron Biomedical has an EPS (earnings per share) of $0.10.

See more trading valuation data for Jafron Biomedical
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$2B$2B0.6%0.6%3.8%-13.8%$0.10

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

Jafron Biomedical Valuation Multiples

Jafron Biomedical trades at 6.4x EV/Revenue multiple, and 13.3x EV/EBITDA.

See NTM and 2027E valuation multiples for Jafron Biomedical

EV / Revenue (LTM)


Jafron Biomedical Financial Valuation Multiples

As of June 2, 2026, Jafron Biomedical has market cap of $2B and EV of $2B.

Jafron Biomedical has a P/E ratio of 25.2x.

LTMLast FY202320242025202620272028
EV/Revenue6.4x6.6x6.9x4.9x6.6x
EV/EBITDA13.3x13.4x19.7x11.0x15.8x
EV/EBIT17.7x17.8x25.2x12.6x17.8x
EV/Gross Profit8.1x8.3x8.6x6.1x8.3x
P/E25.2x27.4x33.4x17.8x27.4x
EV/FCF-24.0x19.7x16.2x24.0x

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified Jafron Biomedical Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

Jafron Biomedical Margins & Growth Rates

Jafron Biomedical grew revenue by 7% and EBITDA by 3% in the last fiscal year.

In the most recent fiscal year, Jafron Biomedical reported gross margin of 79%, EBITDA margin of 49%, and net margin of 26%.

See estimated margins and future growth rates for Jafron Biomedical

Jafron Biomedical Margins

Last FY202420252026202720282029
Gross Margin79%81%79%80%
EBITDA Margin49%45%42%47%
EBIT Margin37%39%37%38%
Net Margin26%31%26%30%
FCF Margin27%30%27%-

Jafron Biomedical Growth Rates

FY+1/FY23/2424/2525/2626/2727/2828/29
Revenue Growth7%39%(25%)7%
Gross Profit Growth9%41%(27%)9%
EBITDA Growth3%79%(30%)21%
EBIT Growth12%99%(29%)12%
Net Profit Growth22%88%(35%)22%
FCF Growth-22%(33%)-

Data powered by FactSet, Inc. and Morningstar, Inc.

Jafron Biomedical Operational KPIs

Jafron Biomedical's Rule of 40 is 54% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Jafron Biomedical's Rule of X is 65% (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Access forward-looking KPIs for Jafron Biomedical
LTMLast FY202320242025202620272028
Rule of 4056%54%---
Bessemer Rule of X69%65%---
S&M Expenses to Revenue25%25%19%15%13%
G&A Expenses to Revenue7%6%3%3%1%
R&D Expenses to Revenue10%10%13%9%10%
Opex to Revenue-42%53%42%42%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

Jafron Biomedical Competitors

Jafron Biomedical competitors include Nektar Therapeutics, Pfizer India, BioCryst Pharma, Jeol, Avadel Pharmaceuticals, Cosmo Pharmaceuticals, SK Bioscience, Mehow Innovative, BioKangtai and OneSource Specialty.

Most Jafron Biomedical public comparables operate across Biopharmaceuticals, Medical Devices, BioTech, DeepTech and HealthTech.

EV/RevenueEV/EBITDA
Last FYLTM2027ELast FYLTM2027E
Nektar Therapeutics30.3x33.9x(13.0x)(9.2x)
Pfizer India7.0x6.9x16.9x19.3x
BioCryst Pharma3.2x3.5x7.9x-
Jeol1.7x1.9x11.1x10.5x
Avadel Pharmaceuticals-0.4x-0.7x
Cosmo Pharmaceuticals-16.2x-154.2x
SK Bioscience4.1x4.0x193.0x(32.5x)
Mehow Innovative7.8x7.0x29.3x26.5x

This data is available for Pro users. Sign up to see all Jafron Biomedical competitors and their valuation data.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About Jafron Biomedical

When was Jafron Biomedical founded?Jafron Biomedical was founded in 1989.
Where is Jafron Biomedical headquartered?Jafron Biomedical is headquartered in China.
Is Jafron Biomedical publicly listed?Yes, Jafron Biomedical is a public company listed on Shenzhen Stock Exchange.
What is the stock symbol of Jafron Biomedical?Jafron Biomedical trades under 300529 ticker.
When did Jafron Biomedical go public?Jafron Biomedical went public in 2016.
Who are competitors of Jafron Biomedical?Jafron Biomedical main competitors include Nektar Therapeutics, Pfizer India, BioCryst Pharma, Jeol, Avadel Pharmaceuticals, Cosmo Pharmaceuticals, SK Bioscience, Mehow Innovative, BioKangtai, OneSource Specialty.
What is the current market cap of Jafron Biomedical?Jafron Biomedical's current market cap is $2B.
What is the current revenue of Jafron Biomedical?Jafron Biomedical's last 12 months revenue is $305M.
What is the current revenue growth of Jafron Biomedical?Jafron Biomedical revenue growth (NTM/LTM) is 8%.
What is the current EV/Revenue multiple of Jafron Biomedical?Current revenue multiple of Jafron Biomedical is 6.4x.
What is the current EBITDA of Jafron Biomedical?Jafron Biomedical's last 12 months EBITDA is $147M.
What is Jafron Biomedical's EBITDA margin?Jafron Biomedical's last 12 months EBITDA margin is 48%.
What is the current EV/EBITDA multiple of Jafron Biomedical?Current EBITDA multiple of Jafron Biomedical is 13.3x.
How many companies Jafron Biomedical has acquired to date?Jafron Biomedical hasn't acquired any companies yet (or none have been disclosed publicly).
In how many companies Jafron Biomedical has invested to date?Jafron Biomedical hasn't invested in any companies yet (or none have been disclosed publicly).

See public comps similar to Jafron Biomedical

Lists including Jafron Biomedical

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial